Pathstone Family Office’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Pathstone Family Office’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,000	Closed	-$3K	–	1412
2020 Q4	$3K	Hold	1,000	–	–	﹤0.01%	1005
2020 Q3	$3K	Hold	1,000	–	–	﹤0.01%	693
2020 Q2	$3K	Hold	1,000	–	–	﹤0.01%	612
2020 Q1	$4K	Buy	+1,000	New	+$4.64K	﹤0.01%	648
2019 Q4	–	Sell	-1,000	Closed	-$8K	–	651
2019 Q3	$8K	Buy	+1,000	New	+$11.3K	﹤0.01%	512
2019 Q2	–	Sell	-1,000	Closed	-$5K	–	944
2019 Q1	$5K	Buy	+1,000	New	+$4.87K	﹤0.01%	612

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pathstone Family Office's ZYNE Position: Q1 2021 in Review

Pathstone Family Office sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2021, closing a stake of 1,000 shares — an estimated $3K sold.

Pathstone Family Office first reported a position in ZYNE in Q1 2019 and held it in 6 quarters. The position peaked at $8K in Q3 2019. 67 funds tracked by Wall St. Rank hold ZYNE as of Q1 2021.

Pathstone Family Office reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2021 after selling out during the quarter.
Pathstone Family Office sold 1,000 Zynerba Pharmaceuticals, Inc shares in Q1 2021, an estimated $3K.
Pathstone Family Office first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2019 and held it in 6 quarters.
Pathstone Family Office's Zynerba Pharmaceuticals, Inc position peaked at $8K in Q3 2019.
67 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2021.

Based on Pathstone Family Office's 13F filing for Q1 2021, filed 14 May 2021.